Corcept Therapeutics focuses on cortisol modulation in pursuit of novel treatments for severe disorders, including endocrinology, oncology, metabolism, and neurology. This is self-described.

Corcept Therapeutics

Domain Not Resolving

HSTS

reCAPTCHA

Cloudflare CDN

Cloudflare Hosting

Cloudflare

jQuery CDN

COVID-19

Gravity Forms

DigiCert SSL

Chief Financial Officer

Atabak Mokari

President

Bob Roe

Chief Business Officer

Charlie Robb

Owner

David Cram

Chief Scientific Officer

Hazel Hunt

Chief Executive Officer

Joe Belanoff

Senior Vice President, Commercial

Sean Maduck

Chief Development Officer (CDO)

William Guyer

Vice President, Clinical Operations

Alan Arroyo

Vice President, Development Operations

Amiel Balagtas

Patrick Enright

David Mahoney

Daniel M. Bradbury

Gregg H. Alton

Jim Wilson

Joseph Turner

Joseph K. Belanoff

Roberto Vieira

President, Oncology

Rob Adamoski

Vice President Marketing and Training

Yuan Xu

Senior Manager, Statistical Programming

United States Public Companies With More Than $10M in Revenue

Biotechnology Public Companies With More Than 100 Employees

Companies That Exited in 2012

Western US Biotechnology Companies

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening.

Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Post-IPO Equity - Corcept Therapeutics

Paperboy Ventures

Venture Round - Corcept Therapeutics

Menlo Park

California

United States

North America

Corcept Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Earnings call: Corcept Therapeutics reports strong Q2 growth, updates pipeline

Corcept Therapeutics reaches all-time high at 35.2214 USD

Corcept Therapeutics Joins Elite List Of Stocks With 95-Plus Composite Rating

Teva sues Corcept over mifepristone 'monopoly' for rare disorder

Stocks Flashing Renewed Technical Strength: Corcept Therapeutics

Corcept Therapeutics announces Phase 3 GRACE trial meets primary endpoint

Palo Alto Networks director McCarthy sells over $312k in company stock By Investing.com

Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?

India

Asia

Italy

Europe

Macedonia

Pakistan

HTML5

MailChannels Cloud

Office 365

Google Compute Engine

Apache Server

jQuery

Wordpress

F5 NGINX

Google Tag Manager

DigiCert

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 6:08 AM	d292250a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 6:08 AM	4edc2bdf
crunchbase trigger	general	Oct 29, 2024 5:10 PM	2696c327
crunchbase profile	general	Oct 30, 2024 12:43 AM	5afd9d79
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	2e462a6c
peers	general	Oct 16, 2024 6:08 AM	67dfc79c
news basic	general	Oct 16, 2024 6:08 AM	4bd208a4
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CORCEPT

Corcept Therapeutics

Last Close

55.92

22/11 21:00

Market Cap

3.19B

Beta: -

Volume Today

648.55K

Avg: -